Treatment Trials

87 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
      Description

      This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Childhood Choroid Plexus TumorChildhood EpendymoblastomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood MedulloepitheliomaRecurrent Childhood Anaplastic AstrocytomaRecurrent Childhood Anaplastic OligoastrocytomaRecurrent Childhood Anaplastic OligodendrogliomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood Giant Cell GlioblastomaRecurrent Childhood GlioblastomaRecurrent Childhood Gliomatosis CerebriRecurrent Childhood GliosarcomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
      Talk to us
      WITHDRAWN
      Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
      Description

      This pilot clinical trial studies gallium Ga 68-edotreotide (68Ga-DOTATOC) positron emission tomography (PET)/computed tomography (CT) in finding brain tumors in younger patients. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT imaging, may help find and diagnose brain tumors.

      Conditions
      Acoustic SchwannomaAdult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic MeningiomaAdult Anaplastic OligodendrogliomaAdult Brain Stem GliomaAdult Choroid Plexus TumorAdult CraniopharyngiomaAdult Diffuse AstrocytomaAdult EpendymoblastomaAdult EpendymomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Grade I MeningiomaAdult Grade II MeningiomaAdult MedulloblastomaAdult Meningeal HemangiopericytomaAdult Mixed GliomaAdult Myxopapillary EpendymomaAdult OligodendrogliomaAdult Papillary MeningiomaAdult Pilocytic AstrocytomaAdult Pineal Gland AstrocytomaAdult PineoblastomaAdult PineocytomaAdult Subependymal Giant Cell AstrocytomaAdult SubependymomaAdult Supratentorial Primitive Neuroectodermal Tumor (PNET)Childhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Supratentorial EpendymomaMeningeal MelanocytomaNewly Diagnosed Childhood EpendymomaRecurrent Adult Brain TumorRecurrent Childhood Anaplastic AstrocytomaRecurrent Childhood Anaplastic OligoastrocytomaRecurrent Childhood Anaplastic OligodendrogliomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood Diffuse AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Fibrillary AstrocytomaRecurrent Childhood Gemistocytic AstrocytomaRecurrent Childhood Giant Cell GlioblastomaRecurrent Childhood GlioblastomaRecurrent Childhood Gliomatosis CerebriRecurrent Childhood GliosarcomaRecurrent Childhood MedulloblastomaRecurrent Childhood OligoastrocytomaRecurrent Childhood OligodendrogliomaRecurrent Childhood Pilocytic AstrocytomaRecurrent Childhood Pilomyxoid AstrocytomaRecurrent Childhood PineoblastomaRecurrent Childhood Pleomorphic XanthoastrocytomaRecurrent Childhood Protoplasmic AstrocytomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaUntreated Childhood Anaplastic AstrocytomaUntreated Childhood Anaplastic OligodendrogliomaUntreated Childhood Brain Stem GliomaUntreated Childhood Cerebellar AstrocytomaUntreated Childhood Cerebral AstrocytomaUntreated Childhood Diffuse AstrocytomaUntreated Childhood Fibrillary AstrocytomaUntreated Childhood Gemistocytic AstrocytomaUntreated Childhood Giant Cell GlioblastomaUntreated Childhood GlioblastomaUntreated Childhood Gliomatosis CerebriUntreated Childhood GliosarcomaUntreated Childhood MedulloblastomaUntreated Childhood OligoastrocytomaUntreated Childhood OligodendrogliomaUntreated Childhood Pilocytic AstrocytomaUntreated Childhood Pilomyxoid AstrocytomaUntreated Childhood PineoblastomaUntreated Childhood Pleomorphic XanthoastrocytomaUntreated Childhood Protoplasmic AstrocytomaUntreated Childhood Subependymal Giant Cell AstrocytomaUntreated Childhood Supratentorial Primitive Neuroectodermal TumorUntreated Childhood Visual Pathway and Hypothalamic GliomaUntreated Childhood Visual Pathway Glioma
      Talk to us
      TERMINATED
      18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
      Description

      To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.

      Conditions
      Adult Anaplastic EpendymomaAdult Anaplastic OligodendrogliomaAdult Brain Stem GliomaAdult Diffuse AstrocytomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Mixed GliomaAdult OligodendrogliomaAdult Pilocytic AstrocytomaAdult Pineal Gland AstrocytomaAdult Subependymal Giant Cell AstrocytomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaRecurrent Adult Brain TumorRecurrent Childhood Anaplastic AstrocytomaRecurrent Childhood Anaplastic OligoastrocytomaRecurrent Childhood Anaplastic OligodendrogliomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood Diffuse AstrocytomaRecurrent Childhood Fibrillary AstrocytomaRecurrent Childhood Gemistocytic AstrocytomaRecurrent Childhood Giant Cell GlioblastomaRecurrent Childhood GlioblastomaRecurrent Childhood Gliomatosis CerebriRecurrent Childhood GliosarcomaRecurrent Childhood OligoastrocytomaRecurrent Childhood OligodendrogliomaRecurrent Childhood Pilomyxoid AstrocytomaRecurrent Childhood Protoplasmic AstrocytomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaUntreated Childhood Anaplastic AstrocytomaUntreated Childhood Anaplastic OligoastrocytomaUntreated Childhood Anaplastic OligodendrogliomaUntreated Childhood Brain Stem GliomaUntreated Childhood Cerebellar AstrocytomaUntreated Childhood Cerebral AstrocytomaUntreated Childhood Diffuse AstrocytomaUntreated Childhood Fibrillary AstrocytomaUntreated Childhood Gemistocytic AstrocytomaUntreated Childhood Giant Cell GlioblastomaUntreated Childhood GlioblastomaUntreated Childhood Gliomatosis CerebriUntreated Childhood GliosarcomaUntreated Childhood OligoastrocytomaUntreated Childhood OligodendrogliomaUntreated Childhood Pilomyxoid AstrocytomaUntreated Childhood Protoplasmic AstrocytomaUntreated Childhood Subependymal Giant Cell AstrocytomaUntreated Childhood Visual Pathway and Hypothalamic GliomaUntreated Childhood Visual Pathway Glioma
      Talk to us
      COMPLETED
      Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
      Description

      This phase II trial studies how well sunitinib malate works in treating younger patients with recurrent, refractory, or progressive malignant glioma or ependymoma. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Childhood Cerebellar Anaplastic AstrocytomaChildhood Cerebral Anaplastic AstrocytomaChildhood Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Subependymal Giant Cell Astrocytoma
      Talk to us
      TERMINATED
      Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
      Description

      This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood Infratentorial EpendymomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaGonadotroph AdenomaPituitary Basophilic AdenomaPituitary Chromophobe AdenomaPituitary Eosinophilic AdenomaProlactin Secreting AdenomaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Spinal Cord NeoplasmRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent Pituitary TumorRecurrent/Refractory Childhood Hodgkin LymphomaT-cell Childhood Acute Lymphoblastic LeukemiaT-cell Large Granular Lymphocyte LeukemiaTSH Secreting AdenomaUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      COMPLETED
      Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
      Description

      This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating young patients with relapsed or refractory primary brain tumors or spinal cord tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug.

      Conditions
      Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Embryonal TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaExtra-adrenal ParagangliomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Spinal Cord NeoplasmRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic Glioma
      Talk to us
      COMPLETED
      Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
      Description

      This phase I trial is studying the side effects and best dose of vorinostat when given together with bortezomib in treating young patients with refractory or recurrent solid tumors, including CNS tumors and lymphoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

      Conditions
      Childhood Burkitt LymphomaChildhood Central Nervous System ChoriocarcinomaChildhood Central Nervous System Germ Cell TumorChildhood Central Nervous System GerminomaChildhood Central Nervous System Mixed Germ Cell TumorChildhood Central Nervous System TeratomaChildhood Central Nervous System Yolk Sac TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaChildhood MedulloepitheliomaChildhood MeningiomaChildhood Mixed GliomaChildhood Nasal Type Extranodal NK/T-cell LymphomaChildhood OligodendrogliomaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Central Nervous System Embryonal TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      COMPLETED
      ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
      Description

      This phase I trial is studying the side effects and best dose of ABT-888 when given in combination with temozolomide in treating young patients with recurrent or refractory CNS tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with temozolomide may kill more tumor cells.

      Conditions
      Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Spinal Cord NeoplasmRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic Glioma
      Talk to us
      COMPLETED
      Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
      Description

      The purpose of this study is to collect and store brain tissue samples and blood from children with brain cancer that will be tested in the laboratory. Collecting and storing samples of tumor tissue and blood from patients to test in the laboratory may help the study of cancer in the future.

      Conditions
      Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Cerebral Anaplastic AstrocytomaChildhood Cerebral AstrocytomaChildhood Choroid Plexus NeoplasmChildhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood Infratentorial EpendymomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaEpendymomaNewly Diagnosed Childhood EpendymomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise SpecifiedRecurrent Childhood Visual Pathway Glioma
      Talk to us
      COMPLETED
      Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
      Description

      This phase II trial studies how well cilengitide works in treating younger patients with recurrent or progressive high-grade glioma that has not responded to standard therapy. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor.

      Conditions
      Childhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaRecurrent Childhood Anaplastic AstrocytomaRecurrent Childhood Anaplastic OligoastrocytomaRecurrent Childhood Anaplastic OligodendrogliomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood GlioblastomaRecurrent Childhood Visual Pathway and Hypothalamic Glioma
      Talk to us
      COMPLETED
      Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
      Description

      RATIONALE: Giving high-dose chemotherapy before an autologous stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This clinical trial is studying how well giving busulfan, melphalan, and topotecan hydrochloride together with a stem cell transplant works in treating patients with newly diagnosed or relapsed solid tumor.

      Conditions
      Solid TumorAdult Central Nervous System Germ Cell TumorAdult RhabdomyosarcomaChildhood Central Nervous System Germ Cell TumorChildhood Soft Tissue SarcomaEwing SarcomaMetastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorOvarian Mixed Germ Cell TumorPreviously Untreated Childhood RhabdomyosarcomaRecurrent Adult Brain TumorRecurrent Adult Soft Tissue SarcomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent Extragonadal Germ Cell TumorRecurrent Extragonadal Non-seminomatous Germ Cell TumorRecurrent Malignant Testicular Germ Cell TumorRecurrent NeuroblastomaRecurrent Ovarian Germ Cell TumorRecurrent Wilms Tumor and Other Childhood Kidney TumorsUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      COMPLETED
      Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
      Description

      This phase I trial is studying the side effects and best dose of ispinesib in treating young patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy, such as ispinesib, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing

      Conditions
      Childhood Burkitt LymphomaChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebral AstrocytomaChildhood Spinal Cord NeoplasmChildhood Supratentorial EpendymomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood MedulloblastomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      COMPLETED
      AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
      Description

      This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

      Conditions
      Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Cerebral Anaplastic AstrocytomaChildhood Cerebral AstrocytomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood Infratentorial EpendymomaChildhood OligodendrogliomaChildhood Spinal Cord NeoplasmChildhood Supratentorial EpendymomaRecurrent Childhood Brain NeoplasmRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway Glioma
      Talk to us
      COMPLETED
      Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
      Description

      This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer cells.

      Conditions
      Childhood Burkitt LymphomaChildhood Central Nervous System Germ Cell TumorChildhood Diffuse Large Cell LymphomaChildhood Grade III Lymphomatoid GranulomatosisChildhood Immunoblastic Large Cell LymphomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Childhood Large Cell LymphomaRecurrent Childhood Liver CancerRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway GliomaRecurrent Colon CancerRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent MelanomaRecurrent Nasopharyngeal CancerRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Wilms Tumor and Other Childhood Kidney TumorsRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      COMPLETED
      Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
      Description

      This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.

      Conditions
      Childhood Atypical Teratoid/Rhabdoid TumorChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic Glioma
      Talk to us
      COMPLETED
      Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
      Description

      This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.

      Conditions
      Childhood Central Nervous System Germ Cell TumorChildhood Extragonadal Germ Cell TumorChildhood HepatoblastomaChildhood Hepatocellular CarcinomaChildhood High-grade Cerebral AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood Malignant Ovarian Germ Cell TumorChildhood Malignant Testicular Germ Cell TumorChildhood TeratomaRecurrent Adrenocortical CarcinomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Liver CancerRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Colon CancerRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent Nasopharyngeal CancerRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent Rectal CancerRecurrent Renal Cell Cancer
      Talk to us
      COMPLETED
      Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
      Description

      This phase I trial is studying the side effects and best dose of erlotinib when given with temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor cells.

      Conditions
      Previously Treated Childhood RhabdomyosarcomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent Osteosarcoma
      Talk to us
      COMPLETED
      Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
      Description

      This phase II trial is studying how well tipifarnib works in treating young patients with recurrent or progressive high-grade glioma, medulloblastoma, primitive neuroectodermal tumor, or brain stem glioma. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

      Conditions
      Childhood High-grade Cerebral AstrocytomaChildhood OligodendrogliomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood MedulloblastomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic Glioma
      Talk to us
      COMPLETED
      Cilengitide in Treating Children With Refractory Primary Brain Tumors
      Description

      This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.

      Conditions
      Childhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Brain TumorRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic Glioma
      Talk to us
      COMPLETED
      FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
      Description

      This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

      Conditions
      Blastic Phase Chronic Myelogenous LeukemiaChildhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood Chronic Myelogenous LeukemiaChildhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebral AstrocytomaChildhood Spinal Cord NeoplasmChildhood Supratentorial EpendymomaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRefractory Chronic Lymphocytic LeukemiaRelapsing Chronic Myelogenous LeukemiaUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      COMPLETED
      Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
      Description

      Phase I trial to study the safety of combining O6-benzylguanine with temozolomide in treating children who have recurrent or refractory brain tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. O6-benzylguanine may increase the effectiveness of temozolomide by making tumor cells more sensitive to the drug.

      Conditions
      Childhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood EpendymoblastomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood High-grade Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaChildhood Infratentorial EpendymomaChildhood Low-grade Cerebellar AstrocytomaChildhood Low-grade Cerebral AstrocytomaChildhood MedulloepitheliomaChildhood Mixed GliomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaRecurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood PineoblastomaRecurrent Childhood Subependymal Giant Cell AstrocytomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic Glioma
      Talk to us
      COMPLETED
      Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
      Description

      Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of flavopiridol in treating children who have relapsed or refractory solid tumors or lymphoma.

      Conditions
      Recurrent Childhood Brain Stem GliomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood Large Cell LymphomaRecurrent Childhood Liver CancerRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Malignant Germ Cell TumorRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Childhood Soft Tissue SarcomaRecurrent Childhood Supratentorial Primitive Neuroectodermal TumorRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent OsteosarcomaRecurrent RetinoblastomaRecurrent Wilms Tumor and Other Childhood Kidney TumorsRecurrent/Refractory Childhood Hodgkin LymphomaUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      COMPLETED
      Irinotecan in Treating Children With Refractory Solid Tumors
      Description

      This phase II trial is studying irinotecan to see how well it works in treating children with refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

      Conditions
      Childhood Central Nervous System Germ Cell TumorChildhood Choroid Plexus TumorChildhood CraniopharyngiomaChildhood Grade I MeningiomaChildhood Grade II MeningiomaChildhood Grade III MeningiomaChildhood Infratentorial EpendymomaChildhood OligodendrogliomaChildhood Supratentorial EpendymomaPreviously Treated Childhood RhabdomyosarcomaRecurrent Childhood Cerebellar AstrocytomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood EpendymomaRecurrent Childhood MedulloblastomaRecurrent Childhood RhabdomyosarcomaRecurrent Childhood Visual Pathway and Hypothalamic GliomaRecurrent Childhood Visual Pathway GliomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent OsteosarcomaUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      COMPLETED
      Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma
      Description

      RATIONALE: Imetelstat sodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I clinical trial is studying the side effects and best dose of imetelstat sodium in treating young patients with refractory or recurrent solid tumors or lymphoma.

      Conditions
      Brain and Central Nervous System TumorsLymphomaLymphoproliferative DisorderSmall Intestine CancerUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      COMPLETED
      PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
      Description

      RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or refractory primary central nervous system tumors.

      Conditions
      Brain and Central Nervous System Tumors
      Talk to us
      TERMINATED
      Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
      Description

      RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with ifosfamide, carboplatin, and etoposide may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of dasatinib when given together with ifosfamide, carboplatin, and etoposide and to see how well they work in treating young patients with metastatic or recurrent malignant solid tumors.

      Conditions
      Brain and Central Nervous System TumorsChildhood Germ Cell TumorExtragonadal Germ Cell TumorKidney CancerLiver CancerLymphomaNeuroblastomaOvarian CancerSarcomaTesticular Germ Cell TumorUnspecified Childhood Solid Tumor, Protocol Specific
      Talk to us
      TERMINATED
      MT2004-30: Tomotherapy for Solid Tumors
      Description

      RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation therapy used to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bone marrow radiation therapy followed by an autologous stem cell transplant in treating patients with high-risk or relapsed solid tumors.

      Conditions
      Brain and Central Nervous System TumorsKidney CancerLiver CancerRetinoblastomaSarcoma
      Talk to us
      TERMINATED
      MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
      Description

      RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating young patients with recurrent or refractory CNS cancer.

      Conditions
      Brain and Central Nervous System Tumors
      Talk to us
      COMPLETED
      Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors
      Description

      RATIONALE: Enzastaurin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin in treating young patients with refractory primary brain tumors.

      Conditions
      Brain and Central Nervous System TumorsNeuroblastoma
      Talk to us
      COMPLETED
      Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
      Description

      RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for central nervous system cancer or leptomeningeal metastases. PURPOSE: This phase II trial is studying the side effects and how well iodine I 131 monoclonal antibody 3F8 works in treating patients with central nervous system cancer or leptomeningeal cancer.

      Conditions
      Brain and Central Nervous System TumorsIntraocular MelanomaLung CancerMelanoma (Skin)Metastatic CancerNeuroblastomaOvarian CancerRetinoblastomaSarcomaSmall Intestine Cancer
      Talk to us